This has been my point for some time. In Australia there are something like 5 cardiac surgeons using CardioCel yet there are 150 general
vascular surgeons who might use the patch on a regular basis but who do not presently do . Whom would you target?
Translate this figure to the developed world and we are looking at 9000 surgeons in the USA, EU and China.Where would you market your product? For 7 years for congenital heart repair or the bigger market? Go global and go for the oldies.
Centres by end of year?, page-15
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.14 |
Change
0.140(1.08%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.50 | $13.14 | $559.5K | 42.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1180 | $13.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.35 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |